浙浙江医药@zju_pharma·Jul 9 RepostedRRecordati@recordati·Jul 9Recordati Industries S.p.A. (Milano, Italia). 2024 revenue ~€2.2B. Rare diseases: Carbaglu, Isturisa, Recorlev. General medicine: Lomir, Zanipress. Founded 1926. Family-controlled.11
华华北制药@ncpcFollowThe PROTAC degraded the target protein with DC50 of 1 nM and Dmax of 95%.9:10:22 PM · Jul 9, 20262
聯聯成化學@upi·Jul 9Structure-based design is most effective when combined with SBDD and parallel chemistry.